Status:
COMPLETED
Efficacy and Safety of Cilostazol for the Indication of CSPS
Lead Sponsor:
Korea Otsuka Pharmaceutical Co., Ltd.
Conditions:
Cerebral Infarction
Eligibility:
All Genders
18-80 years
Brief Summary
This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.
Detailed Description
This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction. Qualified patients will be treated with cilostazol by physicia...
Eligibility Criteria
Inclusion
- Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction.
- Age: more than 18 years of age
Exclusion
- Unqualified patients judged by study investigator(s)
Key Trial Info
Start Date :
December 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT00216749
Start Date
December 1 2003
End Date
October 1 2007
Last Update
December 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea